i3 Acquires ChinaGate, Providing Customers With Greater Access to Chinese Market

May 19, 2010
Company News Release

i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization (CRO) that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.

ChinaGate has guided customers – based in China and abroad – through China’s regulatory system to bring medical and consumer health care products to the Chinese market. In addition, ChinaGate has helped its customers bring products manufactured in China to global markets.

ChinaGate has experience with the State Food and Drug Administration (SFDA), China’s regulatory authority charged with oversight and supervision of drugs and medical devices.

ChinaGate’s customers will gain access to development, data, and commercialization services through i3’s global reach. As a subsidiary of Ingenix, i3 offers systems, information, training, learning and development, and enabling technologies.

“ChinaGate will enhance i3’s ability to help our customers expand and sustain their business in the important Chinese market," said Glenn Bilawsky, CEO of i3.

“Combining i3’s and ChinaGate’s knowledge, experience, and expertise will enable us to offer clients more comprehensive services and continued results in one of the world’s fastest-growing pharma and medical-device markets,” said Joyce Chiu, CEO of ChinaGate.

The ChinaGate executive team, led by Chiu and Managing Director Janice Ma, will continue in their roles as ChinaGate integrates with i3’s Clinical Development Services group.

Market Opportunities in China

Global life science companies are increasingly turning to China to establish major research and development (R&D) capabilities and product development services. By 2020, China is targeting an investment of 2.5 percent of GDP into pharmaceutical R&D, putting China into a range comparable with that of the United States.

As disease patterns and prevalence in the Chinese population have begun to resemble those of the West, 75 percent of China’s total drug development pipeline is now in i3’s areas of therapeutic specialization, including oncology, central nervous system diseases, infectious disease, cardiovascular disease, and endocrine/metabolic conditions.